Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Global stock markets trading in green
Fri, 9 Mar 09:30 am

Asian stock markets have opened the day on a firm note. Stock markets in Japan (up 1.5%), Hong Kong (up 0.6%) and China (up 0.4%) are in the green. The Indian stock markets have opened the day on a firm note. Stocks in the realty and metals space are leading the gains.

The BSE-Sensex is trading up by 300 points (2%) and the NSE-Nifty is up by around 90 points (1.9%). Mid cap and small cap stocks are trading in the green as well, with the BSE Mid cap and BSE Small cap indices up by 1.5% and 1% respectively. The rupee is trading at Rs 50.06 to the US dollar.

Auto stocks have opened the day on a weak note with Tata Motors (Telco) and Maruti Suzuki India in the green. Hero MotoCorp has plans to start its global drive from the next quarter. The company wants to start exports to the African Nations and Latin America. The exports will fall under the subsidiary company named as Hero International Business. The company further intends to sell in some of the South-East Asian countries. The company said that the new distributors for the two-wheeler have been finalized. Hero Motocorp is looking to export many different models to these markets. The company might have to set up assembling plants in some of the countries in order to avoid the taxes in some of these countries.

Pharma Stocks have opened the day on a firm note with Ranbaxy and Cipla in the green. The USA subsidiary of Glenmark Pharma has been allowed the final abbreviated new drug approval (ANDA) from the USFDA. This approval is for the Imiquimod Cream 5%, a generic version of Aldara which belongs to Medicis Pharmaceutical Corporation. Glenmark in a notice said that the company has already arranged for sending the shipments to US for the new drud. This cream is used for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses to be used on the face or scalp in adults. It can also be used for cure of external genital and perianal warts in patients above 12 years old. The company said, referring the IMS Health sales data that this cream had garnered around US $ 244 m in sales by December 2011. Glenmark's current portfolio consists of 77 products authorized for distribution in the U.S. marketplace and 40 ANDA's pending approval with the U.S. FDA.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Global stock markets trading in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.